Breast CancerNCT07663006
Breast and Cervical Cancer Stigma in Rwanda
A study testing Behavioral: RISE Intervention and Behavioral: CHW Educational Intervention in people with Breast Cancer and Cervical Cancer, run by Dana-Farber Cancer Institute at 2 sites in Rwanda.
Trial summary
This study aims to assess breast and cervical cancer stigma and pilot a multi-modal intervention to mitigate stigma among patients, caregivers, and community health workers in Rwanda. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Cervical Cancer
- What is being tested?
- Behavioral: RISE Intervention and Behavioral: CHW Educational Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,116 participants
- Where
- 2 sitesRwanda
- Study dates
- 1 Nov 2026to 1 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with pathologically confirmed breast or cervical cancer
- Patients receiving treatment at BCCOE during the study period
- Age 18 and over
- Ability to provide informed consent
- Ability to participate in interview or surveys in English or Kinyarwanda
- Caregiver (including spouses, children, family members or other individuals as designated by patients) of patients with pathologically confirmed breast or cervical cancer who are actively receiving treatment at BCCOE during the study period
Show all 30Show fewer
- Age 18 and over
- Ability to provide informed consent
- Ability to participate in interview or surveys in English or Kinyarwanda
- Healthcare Worker
- Working in a preselected health center, district hospital, provincial hospital in the Northern Province
- Age 18 or older
- Ability to provide informed consent
- Ability to participate in interview or surveys in English or Kinyarwanda
- Healthcare Worker
- Registered with relevant professional organization in Rwanda
- Age 18 or older
- Ability to provide informed consent
- Ability to participate in surveys in English or Kinyarwanda
- Patients with pathologically confirmed breast cancer who are actively receiving curative-intent treatment at BCCOE during the study period and a designated caregiver
- Patients getting systemic neoadjuvant chemotherapy who are expected in the clinic on a 3-week cycle
- Patients who have at least 4 cycles of therapy remaining
- Age 18 and over
- Ability to provide informed consent
- Ability to participate in pilot, interview, and surveys in English or Kinyarwanda
- Community Health Worker registered with relevant healthcare facilities in Northern Rwanda
- Age 18 or older
- Willing to engage in activities related to breast and cervical cancer and to support survivors
- Ability to provide informed consent
- Ability to participate in pilot, interview, and surveys in English or Kinyarwanda
Who cannot join
- Unwilling or Unable to consent to participation.
- Unable to comprehend study language (Kinyarwanda or English)
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment
- Interpersonal interviews and surveys:
Show all 39Show fewer
- Caregivers of the potential patients will be identified from the potential patients. Potential patients will be identified by the clinical team from physical and electronic registries of patients. Potential participants will be screened for eligibility by the study research assistant.
- Unwilling or Unable to consent to participation.
- Unable to comprehend study language (Kinyarwanda or English)
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment
- Institutional Focus group:
- An official participation letter will be sent from BL2TH to leaders of the preselected facilities. Interested participants will be encouraged to contact the study team. Potential participants will be invited by their hospital/center leadership and screened for eligibility by the study research assistant.
- Unwilling or Unable to consent to participation.
- Unable to comprehend study language (Kinyarwanda or English)
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment
- Institutional surveys:
- Formal participation invitation will be sent to the Rwanda Medical and Dental Council, National Council of Nurses and Midwives, and the Rwanda Allied Health Professions Council. Potential participants will be screened for eligibility electronically and informed consent obtained electronically.
- Unwilling or Unable to consent to participation.
- Unable to comprehend study language (Kinyarwanda or English)
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment
- Aim 2 Inclusion and Exclusion Criteria Aim 2 Intervention pilot (patient, caregivers and community health workers)
- Patient and Caregiver Pilot:
- Unwilling or Unable to consent to participation.
- Unable to comprehend study language (Kinyarwanda or English)
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment
- Community Health Worker Pilot:
- Unwilling or Unable to consent to participation
- Unable to comprehend study language (Kinyarwanda or English)
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Pregnant women
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Rwanda2 sites
Butaro Level 2 Teaching Hospital (BL2TH), Ministry of Health
Butaro
Eulade Rugengamanzi, MD, +250 783 849 767, erugengamanzi@ughe.org
Eulade Rugengamanzi, MD
University of Global Health Equity (UGHE)
Butaro
Eulade Rugengamazi, MD, +250 783 849 767, erugengamanzi@ughe.org
Eulade Rugengamazi, MD
About this study
Official title: Assessing Breast and Cervical Cancer Stigma and Piloting a Mitigating Intervention in Rwanda
This study aims to assess breast and cervical cancer stigma and pilot a multi-modal intervention to mitigate stigma among patients, caregivers, and community health workers in Rwanda. The elements include resilience training (patient), support group (caregivers), or exposure to survivors by video and in-person (patient, caregivers, and community health workers), and educational curriculum (community health workers).
Read the detailed description
The aim of this research study is to pilot components of an intervention to reduce the impact breast and cervical cancer stigma on patients and caregivers to improve the patient care experience and patient outcomes. The study seeks to achieve two goals. The first, to understand how stigma (negative attitudes, shame, or discrimination) related to breast and cervical cancer shows up in Rwanda-for patients, within families and caregiving relationships, and across the healthcare system. To do this, the team will use a combination of surveys and in-depth conversations to capture both numbers and lived experiences.
The second study aim is to co-develop culturally appropriate, community-informed interventions that translate research findings into practical supportive care strategies for cancer patients and caregivers. A Community Advisory Board comprising survivors, caregivers, community health workers, nurses, social workers, mental health professionals, and an oncologist will guide intervention development and implementation. Using a community-based participatory approach and intervention mapping, the team will design the RISE program, which includes: (1) resilience skills training for patients delivered in four group sessions aligned with chemotherapy cycles; (2) peer support groups for caregivers addressing caregiving burden, emotional well-being, stigma, communication, and community resources; and (3) survivor-informed videos presenting lived experiences and coping strategies.
Approximately 1,086 participants will be enrolled.
- Conditions
- Breast Cancer, Cervical Cancer
- Being tested
- Behavioral: RISE Intervention, Behavioral: CHW Educational Intervention
- Keywords
- Breast Cancer, Cervical Cancer, Cancer Stigma
- Medical subject headings
- Breast Neoplasms, Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioral: RISE InterventionBehavioural
Components: Resilience skills building (psychoeducation), peer-to-peer support groups, exposure to survivors via video storytelling Target: Patients with breast cancer and their caregivers
Behavioral: CHW Educational InterventionBehavioural
Components: Exposure to survivors (video storytelling), educational curriculum (presentation, booklet, video) Target: Community health workers
| Study group | Role | What they receive |
|---|---|---|
| Patient and Caregiver Intervention (RISE) | Experimental | Patients with breast cancer and their caregivers will receive the RISE intervention, which includes resilience skills building (patients), peer-to-peer support groups (caregivers), and exposure to survivors through video storytelling (both). Receives: Behavioral: Behavioral: RISE Intervention |
| Community Health Worker (CHW) Intervention | Experimental | Community health workers will receive exposure to survivors' components and an educational curriculum delivered via presentation, booklet, and video. Receives: Behavioral: Behavioral: CHW Educational Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Cancer Stigma
Cancer-related stigma will be assessed using validated and adapted survey instruments among patients, caregivers, and healthcare workers. The primary outcome is the prevalence of stigma based on the adapted scale. The investigators will also assess stigma in different subgroups based on demographic, and clinical characteristics.
Measured: Baseline
Change in Cancer-Related Stigma Score
The outcome is defined as the change in stigma score from baseline to post-intervention among participants, with higher reductions indicating improvement in stigma.
Measured: Baseline and within 4 weeks following completion of the pilot intervention (approximately 4-5 months)
Rate of Acceptability of Intervention Components
Acceptability of the intervention components will be evaluated using the Acceptability of Intervention Measure (AIM). The outcome is defined as the proportion (percentage) of participants with a total AIM score ≥16 (range of scores 4 - 20), based on 4 items rated on a 5-point Likert scale (1 = completely disagree to 5 = completely agree), with higher percentages indicating greater acceptability.
Measured: Within 4 weeks following completion of the intervention delivery period (approximately Month 13)
Rate of Appropriateness of Intervention Components
Appropriateness of the intervention components will be evaluated using the Intervention Appropriateness Measure (IAM). The outcome is defined as the proportion (percentage) of participants with a total IAM score ≥16 (range of scores 4 - 20), based on 4 items rated on a 5-point Likert scale, with higher percentages indicating greater perceived appropriateness.
Measured: Within 4 weeks following completion of the intervention delivery period (approximately Month 13)
Rate of Feasibility of Intervention Components
Feasibility of the intervention components will be evaluated using the Feasibility of Intervention Measure (FIM). The outcome is defined as the proportion (percentage) of participants with a total FIM score ≥16 (range of scores 4 - 20), based on 4 items rated on a 5-point Likert scale, with higher percentages indicating greater feasibility.
Measured: Within 4 weeks following completion of the intervention delivery period (approximately Month 13)
Secondary outcomes (2)
Qualitative Themes of Cancer Stigma Across Socioecological Levels- individual interviews
Cancer stigma will be qualitatively assessed from the joint qualitative analysis of individual interviews. The outcome consists of identified themes related to stigma, which will be categorized and mapped to domains of the Health Stigma and Discrimination (HSD) framework.
Measured: During the socioecological stigma assessment phase (approximately Month 2 through Month 13).
Qualitative Themes of Cancer Stigma Across Socioecological Levels- focus groups
Cancer stigma will be qualitatively assessed from the joint qualitative analysis of focus groups. The outcome consists of identified themes related to stigma, which will be categorized and mapped to domains of the Health Stigma and Discrimination (HSD) framework.
Measured: During the socioecological stigma assessment phase (approximately Month 2 through Month 13).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Dana-Farber Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,116 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Dana-Farber/Harvard Cancer Center (DF/HCC) Boston, MA, American Association for Cancer Research, Breast Cancer Research Foundation
- Responsible party
- Principal investigator, Temidayo Fadelu, MD, Dana-Farber Cancer Institute
- Investigators
- Temidayo Fadelu, MD, Principal investigator, Dana-Farber Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07663006
- Sponsor's protocol ID
- 25-837
- Status last verified
- Jun 2026
- First submitted
- 22 May 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing Breast and Cervical Cancer Stigma and Piloting a Mitigating Intervention in Rwanda
- ClinicalTrials.gov ID
- NCT07663006
- Acronym / sponsor ID
- 25-837
- Conditions
- Breast Cancer, Cervical Cancer
- Keywords
- Breast Cancer, Cervical Cancer, Cancer Stigma
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,116 participants (estimated)
- Lead sponsor
- Dana-Farber Cancer InstituteUniversity, hospital or other
- Collaborators
- Dana-Farber/Harvard Cancer Center (DF/HCC) Boston, MA, American Association for Cancer Research, Breast Cancer Research Foundation
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 1 Dec 2027 (estimated)
- Study completion
- 1 Dec 2029 (estimated)
- First posted
- 23 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to assess breast and cervical cancer stigma and pilot a multi-modal intervention to mitigate stigma among patients, caregivers, and community health workers in Rwanda. The elements include resilience training (patient), support group (caregivers), or exposure to survivors by video and in-person (patient, caregivers, and community health workers), and educational curriculum (community health workers).
Detailed description
The aim of this research study is to pilot components of an intervention to reduce the impact breast and cervical cancer stigma on patients and caregivers to improve the patient care experience and patient outcomes. The study seeks to achieve two goals. The first, to understand how stigma (negative attitudes, shame, or discrimination) related to breast and cervical cancer shows up in Rwanda-for patients, within families and caregiving relationships, and across the healthcare system. To do this, the team will use a combination of surveys and in-depth conversations to capture both numbers and lived experiences.
The second study aim is to co-develop culturally appropriate, community-informed interventions that translate research findings into practical supportive care strategies for cancer patients and caregivers. A Community Advisory Board comprising survivors, caregivers, community health workers, nurses, social workers, mental health professionals, and an oncologist will guide intervention development and implementation. Using a community-based participatory approach and intervention mapping, the team will design the RISE program, which includes: (1) resilience skills training for patients delivered in four group sessions aligned with chemotherapy cycles; (2) peer support groups for caregivers addressing caregiving burden, emotional well-being, stigma, communication, and community resources; and (3) survivor-informed videos presenting lived experiences and coping strategies.
Approximately 1,086 participants will be enrolled.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patient and Caregiver Intervention (RISE) | Experimental | Behavioral: Behavioral: RISE InterventionPatients with breast cancer and their caregivers will receive the RISE intervention, which includes resilience skills building (patients), peer-to-peer support groups (caregivers), and exposure to survivors through video storytelling (both). |
| Community Health Worker (CHW) Intervention | Experimental | Behavioral: Behavioral: CHW Educational InterventionCommunity health workers will receive exposure to survivors' components and an educational curriculum delivered via presentation, booklet, and video. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (30 listed)
- Patients with pathologically confirmed breast or cervical cancer
- Patients receiving treatment at BCCOE during the study period
- Age 18 and over
- Ability to provide informed consent
- Ability to participate in interview or surveys in English or Kinyarwanda
Key exclusion criteria (39 listed)
- Unwilling or Unable to consent to participation.
- Unable to comprehend study language (Kinyarwanda or English)
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Behavioral: RISE InterventionComponents: Resilience skills building (psychoeducation), peer-to-peer support groups, exposure to survivors via video storytelling Target: Patients with breast cancer and their caregivers | Behavioural | Patient and Caregiver Intervention (RISE) |
| Behavioral: CHW Educational InterventionComponents: Exposure to survivors (video storytelling), educational curriculum (presentation, booklet, video) Target: Community health workers | Behavioural | Community Health Worker (CHW) Intervention |
Primary outcome
Prevalence of Cancer Stigma
Time frame: Baseline
Cancer-related stigma will be assessed using validated and adapted survey instruments among patients, caregivers, and healthcare workers. The primary outcome is the prevalence of stigma based on the adapted scale. The investigators will also assess stigma in different subgroups based on demographic, and clinical characteristics.
Change in Cancer-Related Stigma Score
Time frame: Baseline and within 4 weeks following completion of the pilot intervention (approximately 4-5 months)
The outcome is defined as the change in stigma score from baseline to post-intervention among participants, with higher reductions indicating improvement in stigma.
Rate of Acceptability of Intervention Components
Time frame: Within 4 weeks following completion of the intervention delivery period (approximately Month 13)
Acceptability of the intervention components will be evaluated using the Acceptability of Intervention Measure (AIM). The outcome is defined as the proportion (percentage) of participants with a total AIM score ≥16 (range of scores 4 - 20), based on 4 items rated on a 5-point Likert scale (1 = completely disagree to 5 = completely agree), with higher percentages indicating greater acceptability.
Rate of Appropriateness of Intervention Components
Time frame: Within 4 weeks following completion of the intervention delivery period (approximately Month 13)
Appropriateness of the intervention components will be evaluated using the Intervention Appropriateness Measure (IAM). The outcome is defined as the proportion (percentage) of participants with a total IAM score ≥16 (range of scores 4 - 20), based on 4 items rated on a 5-point Likert scale, with higher percentages indicating greater perceived appropriateness.
Rate of Feasibility of Intervention Components
Time frame: Within 4 weeks following completion of the intervention delivery period (approximately Month 13)
Feasibility of the intervention components will be evaluated using the Feasibility of Intervention Measure (FIM). The outcome is defined as the proportion (percentage) of participants with a total FIM score ≥16 (range of scores 4 - 20), based on 4 items rated on a 5-point Likert scale, with higher percentages indicating greater feasibility.
2 secondary outcomes
Qualitative Themes of Cancer Stigma Across Socioecological Levels- individual interviews
Time frame: During the socioecological stigma assessment phase (approximately Month 2 through Month 13).
Qualitative Themes of Cancer Stigma Across Socioecological Levels- focus groups
Time frame: During the socioecological stigma assessment phase (approximately Month 2 through Month 13).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
- Individual participant dataSharing planned: Yes. The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Temidayo Fadelu, MD principal investigator
Dana-Farber Cancer Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Behavioral: RISE Intervention and Behavioral: CHW Educational Intervention in people with Breast Cancer and Cervical Cancer, run by Dana-Farber Cancer Institute at 2 sites in Rwanda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 30 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Rwanda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Temidayo Fadelu, MD (+1 617-632-3779, temidayo_fadelu@dfci.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of Cancer Stigma (time frame: Baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.